Neurotoxicity Research

, 12:275 | Cite as

Botulinum neurotoxin: Evolution from poison, to research tool - onto medicinal therapeutic and future pharmaceutical panacea

  • Richard M. KostrzewaEmail author
  • Juan Segura-Aguilar


Botulinum neurotoxin (BoNT), for more than a hundred years, has been a recognized poisonous principle in spoiled food. As its chemical structure became unraveled, and as more knowledge was gained over its mechanism of toxicity, it became clear that BoNT had the potential to act therapeutically as a targeted toxin that could inactivate specific nerve populations, and thus achieve a therapeutic goal. BoNT has evolved over the past 25 years into a viable therapeutic, now being a first line treatment for dystonia, overtly altering the course of progression of this disorder. BoNT is used for hyperhidrosis and gustatory sweating syndrome, alleviation of pain, as a treatment for overactive bladder, achalasia and anal fissure; and it has gained popularity as a cosmetic aid. Many other possible uses are being explored. The greatest potential for BoNT may lie in its being a molecular Trojan Horse — able to carry a specific enzyme or specific drug to the inside of a cancer or other type of cell while bypassing other cells and thereby having little or no ill effect. BoNTs pharmaceutical potential is boundless.


Botulinum neurotoxin Pharmaceutical Neuromuscular junction Dystonia Spasticity Bladder Cosmetic aid 


  1. Abbruzzese and A Berardelli (2006) Neurophysiological effects of botulinum toxin type A.Neurotox. Res. 9, 109–114.PubMedGoogle Scholar
  2. Adekar SP, MD Elias, KA Rybinski, F al-Saleem, AB Maksymowych, LL Simpson and SK Dessain (2006) Human antibodies that bind botulinum neurotoxin A.Neurotox. Res. 9, 243.Google Scholar
  3. Aguilera J and C Gil (2006) Serotonergic action of tetanus toxin.Neurotox. Res. 9, 233.Google Scholar
  4. Albanese A and G Brisinda (2006) Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin.Neurotox. Res. 9, 222.Google Scholar
  5. Aoki KR, A Satorius, C Ardila, M Brown, G Nicholson and J Francis (2006) Pharmacology of Botox®, Dysport®, Myobloc and BoNT/A in animal models of efficacy and safety.Neurotox. Res. 9, 236.Google Scholar
  6. Arnon SS, G Claes, L Juarez and J Barash (2006) Post-licensure experience with BabyBIG® for the treatment of infant botulism: the first 18 months.Neurotox. Res. 9, 233.Google Scholar
  7. Atassi MZ, BZ Dolimbek, JJ Jankovic, LE Steward and KR Aoki (2006) Risk factors for botulinum toxin immunoresistance and molecular recognition of toxin-A by antibodies of immunoresistant patients.Neurotox. Res. 9, 223.Google Scholar
  8. Baldwin MR, WH Tepp, CL Pier, M Bradshaw, MF Ho, BA Wilson, RB Fritz, EA Johnson and JT Barbieri (2006) Cross protection of recombinant subunit vaccines against botulism.Neurotox. Res. 9, 243.Google Scholar
  9. Barnes M (2006) Spasticity associated with multiple sclerosis.Neurotox. Res. 9, 220.Google Scholar
  10. Barrick S, W de Groat and L Birder (2006) Regulation of chemical and mechanical-evoked ATP release from urinary bladder urothelium by botulinum toxin type A.Neurotox. Res. 9, 229.Google Scholar
  11. Barron R, C Kozma, M Dickson and LA Koman (2006) Cost of care comparison between cerebral palsy patients treated with botulinum toxin type A (BoNT/A) and propensity score-matched controls.Neurotox. Res. 9, 232.Google Scholar
  12. Benecke R and D Dressler (2007) Botulinum toxin treatment of axial and cervical dystonia.Disabil. Rehabil. 29(23), 1769–1777.PubMedCrossRefGoogle Scholar
  13. Berardelli A (2006) Neurophysiological and clinical effects of botulinum toxin type A.Neurotox. Res. 9, 217.Google Scholar
  14. Berardelli A, C Lorenzano, S Bagnato and F Gilio (2006) Lack of evidence of botulinum toxin diffusion in untreated muscles in patients with hemifacial spasm.Neurotox. Res. 9, 237.Google Scholar
  15. Binz T, A Rummel, T Eichner, T Karmath, S Hahrhold, A Gutcaits, T Weil and H Bigalke (2006) Characterization of the protein receptor binding site of botulinum neurotoxins B and G.Neurotox. Res. 9(2,3), 217.Google Scholar
  16. Binzer M and K Shorsh (2006) Treatment of chronic whiplash associated disorder with botulinum toxin A —a doubleblind placebo controlled crossover study.Neurotox. Res. 9, 229.Google Scholar
  17. Blasi J, A Muhaisen, J Aleu, A Raptis, L Bahima, M Martín-Satué, L Texidó, J Marsal and C Solsona (2006) Modulation of endogenous hemichannels by syntaxin 1A inXenopus oocytes.Neurotox. Res. 9, 242.Google Scholar
  18. Bluemel J, J Frevert and A Schwaier (2006) Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit.Neurotox. Res. 9, 238.Google Scholar
  19. Boyer AE, H Moura, AR Woolfitt, SR Kalb, L McWilliams, JG Schmidt and JR Barr (2006) MALDI-TOF MS and ESI-LC-MS/MS detection and differentiation of the activities of botulinum neurotoxins A-G.Neurotox. Res. 9, 238.Google Scholar
  20. Bozzi Y, L Costantin, F Antonucci and M Caleo (2006) Action of botulinum neurotoxins in the central nervous system: antiepileptic effects.Neurotox. Res. 9(2,3), 197–203.PubMedGoogle Scholar
  21. Brashear A (2006) Patient selection and functional measures in post-stroke spasticity.Neurotox. Res. 9, 220–221.Google Scholar
  22. Brashear A, P Hogan and MW Watts (2006) Dose consistency of botulinum toxin typeA (BoNT/A; Botox®) for cervical dystonia.Neurotox. Res. 9, 231.Google Scholar
  23. Brisinda G, IM Civello, A Albanese and G Maria (2003) Gastrointersinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin.Curr. Med. Chem. 10, 603–623.PubMedCrossRefGoogle Scholar
  24. Brisinda G, G Maria, AR Bentivoglio, F Cadeddu, G Marniga, F Brandara and A Albanese (2006) Management of bladder, prostatic and pelvic floor disorders.Neurotox. Res. 9(2,3), 161–172.PubMedGoogle Scholar
  25. Brunger AT and MA Breidenbach (2006) Structural aspects of SNARE-clostridial neurotoxin interactions.Neurotox. Res. 9, 223.Google Scholar
  26. Brunton LL, JS Lazo and KL Parker (2006)Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition (McGraw-Hill: New York, NY).Google Scholar
  27. Caleo M, L Costantin, C Richichi, A Viegi, F Antonucci, M Funicello, M Gobbi, T Mennini, O Rossetto, C Montecucco, L Maffei, A Vezzani and Y Bozzi (2006) Anti-epileptic effects of botulinum neurotoxin E.Neurotox. Res. 9, 231.Google Scholar
  28. Carpentier B and M Leong (2006) Case report: treatment of post-mastectomy syndrome with botulinum toxin.Neurotox. Res. 9, 228.Google Scholar
  29. Carruthers A and J Carruthers (2006) A single-center, dose-comparison, pilot study of the safety and efficacy of botulinum toxin type A (BoNT/A) in female subjects with upper facial rhytids.Neurotox. Res. 9, 225.Google Scholar
  30. Carruthers J and A Carruthers (2006) Long-term safety review of subjects treated with botulinum toxin type A (BoNT/A) for cosmetic use.Neurotox. Res. 9, 225.Google Scholar
  31. Chaddock JA, RJ Ling, CL Cox, PMH Marks, EM Marks, PR Stancombe, JM Wayne, J Francis, LE Steward, KR Aoki and KA Foster (2006) C-Terminal amidation of the neuropeptide targeting domain of recombinant clostridial endopeptidaseligand fusions.Neurotox. Res. 9, 234.Google Scholar
  32. Chapman ER (2006) Clostridial neurotoxins: receptors, modes of entry, and detection.Neurotox. Res. 9, 219.Google Scholar
  33. Chen R, BI Karp and M Hallett (1998) Botulinum toxin type F for treatment of dystonia: long-term experience. Botulinum toxin type F for treatment of dystonia: long-term experience.Neurology 51, 1494–1496.PubMedGoogle Scholar
  34. Chen S, EA Johnson, M Bradshaw, C Pier and JT Barbieri (2006) The expression and solubility of botulinum neurotoxin light chain E.Neurotox. Res. 9, 233.Google Scholar
  35. Christian T, N Shine, L Eaton and K Crawford (2006) Comparison of activity of botulinum neurotoxin type A holotoxin and light chain using SNAPtide FRET substrates.Neurotox. Res. 9, 239.Google Scholar
  36. Cleveland P, M Leong and M Royal (2006) A review of adult adverse events associated with botulinum toxin type B (Myobloc®).Neurotox. Res. 9, 231.Google Scholar
  37. Comella CL (2007) The treatment of cervical dystonia with botulinum toxins.J. Neural Transm. Nov 12; [Epub ahead of print].Google Scholar
  38. Comella CL, J Jankovic, KM Shannon, J Tsui, M Swenson, S Leurgans, W Fan and Dystonia Study Group (2005) Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 65(9), 1423–1429.PubMedCrossRefGoogle Scholar
  39. Costantin L, Y Bozzi, C Richichi, A Viegi, F Antonucci, M Funicello, M Gobbi, T Mennini, O Rossetto, C Montecucco, L Maffei, A Vezzani and M Caleo (2005) Antiepileptic effects of botulinum neurotoxin E.J. Neurosci. 225, 1943–1951.CrossRefGoogle Scholar
  40. de Boulle K, J Smuts, R van Coller and P Barnard (2006) An electrophysiological study to demonstratein vivo differences between two formulations of botulinum toxin type A (Botox® and Dysport®).Neurotox. Res. 9, 236.Google Scholar
  41. de Seze M, H Petit, P Gallien, MP de Seze, PA Joseph, JM Mazaux and M Barat (2002) Botulinum A toxin and detrusor sphincter dyssnergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.Eur. Urol. 42, 56–62.PubMedCrossRefGoogle Scholar
  42. Deinhardt K, S Bohnert, C Verastegui, O Berninghausen and G Schiavo (2006) Endocytosis and membrane dynamics in motor neurons.Neurotox. Res. 9, 217.Google Scholar
  43. Denys P, B Schurch, E Chartier-Kastler, B Perrouin-Verbe, S Fraczek and R Barron (2006) Quality of life improvements following botulinum toxin A treatment for neurogenic urinary incontinence.Neurotox. Res. 9, 226.Google Scholar
  44. Deshpande S and M Gormley (2006) Muscle fiber orientation in muscles commonly injected with botulinum toxin type A.Neurotox. Res. 9, 245.Google Scholar
  45. Deshpande S, ME Gormley Jr and JR Carey (2006) Muscle fiber orientation in muscles commonly injected with botulinum toxin: an anatomical pilot study.Neurotox. Res. 9(2,3), 115–120.PubMedGoogle Scholar
  46. Dessain SK, SP Adekar, JB Stevens, KA Carpenter, ML Skorski, BL Barnoski, RA Goldsby and RA Weinberg (2004) High efficiency creation of human monoclonal antibody-producing hybridomas.J. Immunol. Meth. 291(1–2), 109–122.CrossRefGoogle Scholar
  47. Doggweiler R, DH Zeimann, M Ishigooka and RA Schmidt (1998) Botox-induced prostatic involution.Prostate 37, 44–50.PubMedCrossRefGoogle Scholar
  48. Dressler D and R Eleopra (2006) Clinical use of non-A botulinum toxins: botulinum toxin type B.Neurotox. Res. 9(2,3), 121–125.PubMedGoogle Scholar
  49. Dressler D, F Adib Saberi and R Benecke (2002) Botulinum toxin type B for treatment of axillary hyperhidrosis.J. Neurol. 249, 1729–1732.PubMedCrossRefGoogle Scholar
  50. Durose LJ, CJ Cruttwell, FCG Alexander, PR Stancombe, CL Cox, JM Sutton, JM Wayne, CC Shone, J Chaddock and KA Foster (2006) Expression and purification ofClostridium botulinum neurotoxin ligand fusions.Neurotox. Res. 9, 235.Google Scholar
  51. Dykstra DD and AA Sidi (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.Arch. Phys. Med. Rehabil. 71, 24–26.PubMedGoogle Scholar
  52. Dykstra D, A Enriquez and M Valley (2003) Treatment of overactive bladder with botulinum toxin type B: a pilot study.Int. Urogynecol. J. Pelvic Floor Dysfunct. 14, 424–426.PubMedCrossRefGoogle Scholar
  53. Dykstra DD, M Stucky, S Schimpff, ML Mahowald and JA Singh (2006) Effects of intra-articular botulinum toxin type A for sacroiliac, cervical/lumbar facet and costosternal joint pain and C-2 root and lumbar disc pain.Neurotox. Res. 9, 227.Google Scholar
  54. Eleopra R, V Tugnoli, R Quatrale, O Rossetto, C Montecucco and D Dressler (2006) Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.Neurotox. Res. 9 (2,3), 127–131.PubMedGoogle Scholar
  55. Elovic E, A Brashear, D Kaelin, R McIntosh, J Liu and C Turkel (2006) Safety and efficacy of repeated botulinum toxin type A treatments for focal upper limb poststroke spasticity: results of a 12-month multicenter, open-label trial.Neurotox. Res. 9, 230.Google Scholar
  56. Evans ER, SP Kidd and CC Shone (2006) Capture of active botulinum neurotoxin (BoNT) from infected media using immunosepharose columns.Neurotox. Res. 9, 239.Google Scholar
  57. Everaert K, Brigitte Schurch, M de Sèze, F Haab and S Fraczek (2006) Efficacy and safety of botulinum toxin A in reversing urodynamic changes caused by neurogenic detrusor overactivity.Neurotox. Res. 9, 226.Google Scholar
  58. Fernández-Salas E, PE Garay, C Iverson, SZ Malik, LE Steward and KR Aoki (2006a) Identification of FGFR3 as a putative receptor for botulinum neurotoxin type A uptake in neuronal cells.Neurotox. Res. 9, 241.Google Scholar
  59. Fernández-Salas E, LE Steward, PE Garay, S Malik, RO Lewis, J Wang, H Ho, SW Sun, MA Gilmore, JV Ordas, J Francis and KR Aoki (2006b) Is light chain subcellular localization a factor influencing botulinum toxin duration of action?Neurotox. Res. 9, 221.Google Scholar
  60. Fischer A and M Montal (2006a) Characterization ofClostridial botulinum neurotoxin channels in neuroblastoma cells.Neurotox. Res. 9, 93–100.Google Scholar
  61. Fischer A and M Montal (2006b) Characterization ofClostridial botulinum neurotoxin channels in neuroblastoma cells.Neurotox. Res. 9, 218.Google Scholar
  62. Foster KA, EJ Adams, L Durose, CJ Cruttwell, E Marks, CC Shone, JA Chaddock, CL Cox, C Heaton, JM Sutton, J Wayne, FCG Alexander and DF Rogers (2006a) Re-engineering the target specificity of clostridial neurotoxins — a route to novel therapeutics.Neurotox. Res. 9(2,3), 101–107.PubMedGoogle Scholar
  63. Foster KA, FCG Alexander, JA Chaddock, CL Cox, CJ Cruttwell, L Durose, C Heaton, E Marks, CC Shone, JM Sutton, J Wayne, EJ Ford, DF Rogers and KR Aoki (2006b) Re-engineering the target specificity of clostridial neurotoxins: a route to novel therapeutics.Neurotox. Res. 9, 222–223.Google Scholar
  64. Foster KA, H Bigalke and K.R. Aoki (2006c) Botulinum neurotoxin toxin — from laboratory to bedside.Neurotox. Res. 9(2,3), 133–140.PubMedGoogle Scholar
  65. Francis J, S You, A Satorius, C Ardila, M Brown, Z Li and KR Aoki (2006) Analgesic properties and mechanism of action of botulinum toxin type A (Botox®).Neurotox. Res. 9, 229.Google Scholar
  66. Francisco AM and SS Arnon (2007) Clinical mimics of infant botulism.Pediatrics 119(4), 826–828.PubMedCrossRefGoogle Scholar
  67. Freund B and M Schwartz (2006) Botulinum toxin type A (Botox®) on quality of life in chronic whiplas.Neurotox. Res. 9, 229.Google Scholar
  68. Frevert J and V Specht (2006) Expression of recombinant di-chain neurotoxins.Neurotox. Res. 9, 234.Google Scholar
  69. Friedenberg FK, A Palit, HP Parkman, A Hanlon and DB Nelson (2007) Botulinum toxin A for the treatment of delayed gastric emptying.Am. J. Gastroenterol. 2007 Dec 5 [Epub ahead of print].Google Scholar
  70. Gaffield M, S Rizzoli and WJ Betz (2006) Differential movements of synaptic vesicles belonging to different vesicle pools.Neurotox. Res. 9, 218–219.Google Scholar
  71. Garcia GE, JJ Ha, D Moorad-Doctor, LY Askins, ML Jewell, H Singh, RH Ratcliffe, DM Calinski, JH Carra and RK Gordon (2006) Buforin inhibitors for botulinum toxin B.Neurotox. Res. 9, 244.Google Scholar
  72. Gazerani P, C Staahl, AM Drewes and L Arendt-Nielsen (2006) Botulinum toxin type A reduces capsaicin-evoked sensory and vasomotor responses in human skin.Neurotox Res. 9, 228.Google Scholar
  73. Geren I, J Lou, C Garcia, A Razai, C Forsyth, T Smith, J Brown, C Perez, WH Tepp, EA Johnson, LA Smith and JD Marks (2006) Recombinant engineered antibody potently neutralizes known and novel A type botulinum neurotoxins.Neurotox. Res. 9, 224.Google Scholar
  74. Gilmore MA, D Williams, LE Steward, Y Okawa, JA Webber, MF Verhagen and KR Aoki (2006) A coupled FRET-fluorescence polarization assay of BoNT proteolytic activity with a fully recombinant substrate.Neurotox. Res. 9, 239.Google Scholar
  75. Glaser DA (2006a) The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome.Neurotox. Res. 9(2,3), 173–178.PubMedGoogle Scholar
  76. Glaver DA (2006b) Use of BoNT for hyperhidrosis, and gustatory sweating.Neurotox. Res. 9, 222.Google Scholar
  77. Goertelmeyer R, S Grafe and G Comes (2006) The blepharospasm disability index (BSDI) — reliability and validity.Neurotox. Res. 9, 237.Google Scholar
  78. Gordon MF and R Barron (2006) Efficacy of repeated treatments with botulinum toxin type A (Botox®) across indications.Neurotox. Res. 9, 238.Google Scholar
  79. Gormley M, G Pries, J Kawiecki, S Quigley and S Deshpande (2006) Adverse events in CP children receiving botolinum toxin type B.Neurotox. Res. 9, 232.Google Scholar
  80. Green N, W Luo and H Fang (2006) High-throughput yeast-cell assays for BoNT proteases.Neurotox. Res. 9, 219.Google Scholar
  81. Gunter J, D Quan, R Martel and S Teal (2006) A prospective study of botulinum toxin A for vestibulodynia.Neurotox. Res. 9, 227.Google Scholar
  82. Han SGR, A Tumuguntla, D Gousse, D Bateman and D Velasquez (2006) Intravesical botulinum toxin type A (BoNT/A) for non-neurogenic overactive bladder (NNOAB) using validated instruments.Neurotox. Res. 9, 225.Google Scholar
  83. Heavner J, M Leong and M Royal (2006) The mind registry: an observational database of patients treated with botulinum toxin type B (Myobloc®) — pain subset of the database.Neurotox. Res. 9, 228.Google Scholar
  84. Heinen F, S Berweck, AS Schroeder and SH Lee (2006) The skills to apply botulinumtoxin — palpation — EMG — muscle stimulation — sonography.Neurotox. Res. 9, 220.Google Scholar
  85. Hoard-Fruchey H, L Smith, JJ Schmidt and M Adler (2006)In vitro stability of botulinum neurotoxin serotypes A and B recombinant light chains in physiological solutions, water, and milk.Neurotox. Res. 9, 244.Google Scholar
  86. Ichtchenko K and PA Band (2006) Full-lengthClostridium botulinum neurotoxin serotype A derivatives with native structure and properties.Neurotox. Res. 9, 234.Google Scholar
  87. James PL, JM Wayne, A Scott-Tucker, PMH Marks, JM Sutton, SM O’Brien, FCG Alexander, CC Shone, JA Chaddock, KR Aoki and KA Foster (2006) Expression and punfication of nontoxic fragments ofClostridium botulinum, neurotoxins.Neurotox. Res. 9, 234.Google Scholar
  88. Jankovic J (2004) Treatment of cervical dystonia with botulimum toxin.Mov. Disord. 19 (Suppl. 8), S109A-S115A.Google Scholar
  89. Jankovic J (2006a) An update on cervical dystonia.Neurotox. Res. 9, 218.Google Scholar
  90. Jankovic J (2006b) Botulinum toxin therapy for cervical dystonia.Neurotox. Res. 9(2,3), 145–148.PubMedGoogle Scholar
  91. Jones RGA, MJC Corbel and D Sesardic (2006) A review of WHO international standards for botulinum antitoxins.Neurotox. Res. 9, 244.Google Scholar
  92. Joo JS, F Agachan, B Wolff, JJ Nogueras and SD Wexner (1996) Initial North American experience with botulinum toxin type A for treatment of anismus.Dis. Colon Rectum 39, 1107–1111.PubMedCrossRefGoogle Scholar
  93. Kalsi V, A Apostolidis, R Popat, R Kavia, I Odeyemi, J Warner, S Elneil, CJ Fowler and P DasGupta (2006) Modelling of the economic impact of using outpatient intradetrusor botulinum toxin-A (BoNT/A) in the treatment of patients with intractable neurogenic (NDO) or idiopathic (IDO) detrus or overactivityNeurotox. Res. 9, 226.Google Scholar
  94. Koman LA, JF Mooney 3rd, BP Smith, F Walker and JM Leon (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blin, placebo-controlled trial BOTOX Study Group.J. Pediatr. Orthop. 20, 108–115.PubMedCrossRefGoogle Scholar
  95. Kozaki S, K Tsukamoto, T Kohda and M Mukamoto (2006) Characterization of receptors forClostridium, botulinum type C and D neurotoxin.Neurotox. Res. 9, 241.Google Scholar
  96. Lackovic Z (2006) Botulinum toxin type A reduces muscle hyperalgesia in the rat.Neurotox. Res. 9, 229.Google Scholar
  97. Lacy BE, MD Crowell, A Schettler-Duncan, C Mathis and PJ Pasricha (2004) The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus.Diabetes Care 10, 2341–2347.CrossRefGoogle Scholar
  98. Lang O, H Bigalke, D Reinhard, F Wegner, M deGroot and K Wohlfarth (2006) Neutralising antibodies and secondary therapy failure after treatment with BoNT/A: much ado about nothing? Abstr. Book, 5th Int’l Conf. on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins.Google Scholar
  99. Laskawi R and M Ellies (2007) The role of botulinum toxin in the management of head and neck cancer patients.Curr Opin. Otolaryngol. Head Neck Surg. 15(2), 112–116.PubMedGoogle Scholar
  100. Laske B, H Taylor, A Rummel and H Bigalke (2006) Validation of anin vitro test to quantify the activity of botulinum neurotoxin type A. Neurotox. Res. 9(2,3),Google Scholar
  101. Leippold T, A Reitz and B Schurch (2003) Botulinum toxin as a new therapy option for voiding disorders current state of the art.Eur. Urol. 44, 165–174.PubMedCrossRefGoogle Scholar
  102. Leong M and M Royal (2006) A randomized double-blind study to compare the efficacy and safety of Neurobloc® (Myobloc®, botulinum toxin type B) with Botox® (botulinum toxin type A) in toxin naïve subjects with cervical dystonia.Neurotox. Res. 9, 245.Google Scholar
  103. Liu Y, RGA Jones and D Sesardic (2006) Development and use of the mouse phrenic nerve hemidiaphragm assay for botulinum type A toxin.Neurotox. Res. 9, 245.Google Scholar
  104. Lorenzano C, S Bagnato, F Gilio, G Fabbrini and A Berardelli (2006) No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm.Neurotox. Res. 9(2,3), 141–144.PubMedGoogle Scholar
  105. Lowe N, R Patnaik and P Lowe (2006) Comparison of two formulations of botulinum toxin type a (BoNT/A) for the treatment of glabellar lines: a double-blind, randomized study.Neurotox. Res. 9, 225.Google Scholar
  106. Luvisetto S, F Marchi, F Lucchetti, F Zuccarelli, S Marinelli and F Pavone (2006) Central and peripheral effects of botulinum neurotoxins on formalin pain.Neurotox. Res. 9, 230.Google Scholar
  107. Mahowald ML, JA Singh and D Dykstra (2006a) Long term effects of intra-articular botulinum toxin A for refractory joint pain.Neurotox. Res. 9(2,3), 179–188.PubMedGoogle Scholar
  108. Mahowald ML, JA Singh and DD Dykstra (2006b) Long-term effects of intra-articular botulinum A toxin (IA-BoNT/A) for refractory joint pain.Neurotox. Res. 9, 227.Google Scholar
  109. Maksymowych AB, DM Ruley, J-B Park and LL Simpson (2006) Identification of a carrier polypeptide for oral and inhalation delivery of drugs and vaccines.Neurotox. Res. 9, 242.Google Scholar
  110. Manno I, F Antonucci, M Caleo and Y Bozzi (2007) BoNT/E prevents seizure-induced activation of caspase 3 in the rat hippocampus.Neuroreport 18, 373–376.PubMedCrossRefGoogle Scholar
  111. Maria G, G Brisinda, AR Bentivoglio, E Cassetta, D Gui and A Albanese (2000) Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure.Am. J. Surg. 179, 46–50.PubMedCrossRefGoogle Scholar
  112. Maria G, G Brisinda, IM Civello AR Bentivoglio, G Sganga and A Albanese (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized placebo-controlled study.Urology 62, 259–264.PubMedCrossRefGoogle Scholar
  113. Marion M-H (2006) Update on botulinum toxin treatment of focal dystonias (excluding cervical dystonia).Neurotox. Res. 9, 218.Google Scholar
  114. Marion M-H and MP Sheehy (2006) Botulinum toxin injections in the treatment of musician’s and artist’s cramps.Neurotox. Res. 9, 231.Google Scholar
  115. Marion MH, K Afors and MP Sheehy (2003) Problems of treating writer’s cramp with botulinum toxin injections: results from 10 years of experience.Rev. Neurol. (Paris) 159 (10 Pt. 1), 923–927.Google Scholar
  116. Mayer NH and A Esquenazi (2006) EMG guidance and electrical stimulation for injection of botulinum toxin.Neurotox. Res. 9, 220.Google Scholar
  117. Meyer JS and LF Quenzer (2005)Psychopharmacology (Sinauer Associates: Sunderland, MA).Google Scholar
  118. Molgó J (2006) Sprouting at the neuromuscular junction and factors influencing the duration of botulinum toxin action.Neurotox. Res. 9, 221.Google Scholar
  119. Molgó J, S Roux, C Colasante, CS Cloment J Barbier, T Curie, E Girard and P Brûlet (2006) Internalization of a GFP-tetanus toxin C-terminal fragment fusion protein at mature mouse neuromuscular junctions.Neurotox. Res. 9, 241.Google Scholar
  120. Morbiato L, J Molgó, L Carli, O Rossetto and C Montecucco (2006) Double injections of different botulinum toxin serotypes in mice and comparison of the duration of action in humans.Neurotox. Res. 9, 233.Google Scholar
  121. Murphy JR (2006) Trojan horse or proton force: finding the right partner(s) for toxin translocation.Neurotox. Res. 9, 219.Google Scholar
  122. Naumann M and NJ Lowe (2001) Botulimun toxin type A in treatment of bilateral primary axillary hyperhidrosis randomized, parallel group, double blind, placebo controlled trial.BMJ 323, 596–599.PubMedCrossRefGoogle Scholar
  123. Neubrand M, C Scheurlen, M Schepke and T Sauerbruch (2002) Long-term results and prognostic factors in the treatment of achalasia with botulinum neurotoxin.Endoscopy 34, 580–581.CrossRefGoogle Scholar
  124. O’Keeffe R, A Pickett, N Panjwani and SL Dodd (2006) Botulimum type A toxin complex (Dysport®) formulated from new batches of bulk active substance has predictable and reproducible activity: results of a novelin vivo rat limb mode.Neurotox. Res. 9, 235.Google Scholar
  125. Oyler GA, YC Tsai, PS Fishman, M Adler and R Kincaid (2006) Trafficking and post-translational modifications at BoNT light chains within cells.Neurotox. Res. 9, 223.Google Scholar
  126. Panjwani N, A Pickett and RS O’Keeffe (2006) Botulinum type A toxins in clinical use: a comparison of specific potency and protein content.Neurotox. Res. 9, 235.Google Scholar
  127. Pasricha PJ (2006) BoNT for gastrointestinal disorders: therapy and mechanisms.Neurotox. Res. 9, 222.Google Scholar
  128. Phelan MW, M Franks, GT Somogyi, T Yokoyama, MO Fraser, JP Lavelle, N Yoshimura and MB Chancellor (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction.J. Urol. 165, 1107–1110.PubMedCrossRefGoogle Scholar
  129. Pickett A, S Shipley, N Panjwani, R O’Keeffe and BR Singh (2006) Characterization and consistency of botulinum type A toxin complex (Dysport®) used for clinical therapy.Neurotox. Res. 9, 235.Google Scholar
  130. Ravichandran E, Y Gong, Fetweh al-Saleem, DM Ancharski, SS Joshi and LL Simpson (2006) Pharmacokinetic studies on botulinum toxin type.Neurotox. Res. 9, 243.Google Scholar
  131. Relia M and S Telarovic (2006) A single blind randomised, parallel study to compare the safety and efficacy of botulinum toxin type-A versus tizanidine in the treatment of cervical dystonia patients.Neurotox. Res. 9, 246.Google Scholar
  132. Reser D, C Braun, D Lochner, K Clarke, M Oster, L Johnson, M Villasin, J Harner, S Chomicz and R Phelps (2006) Imaging Botox® effects on muscle activity using thermal signature analysis.Neurotox. Res. 9, 237.Google Scholar
  133. Ron Y, Y Avni, A Lukovetski, J Wardi, D Geya, S Birkenfeld and Z Halpern (2001) Botulinum toxin type-A in therapy of patients with anismus.Dis. Colon Rectum 44, 1821–1826.PubMedCrossRefGoogle Scholar
  134. Royal M and M Leong (2006) A review of pediatric adverse events associated with botulinum toxin type B (Myobloc®).Neurotox. Res. 9, 232.Google Scholar
  135. Rummel A, U Fuhrmann, B Laske, K Sandhoff, R Proia, T Binz and H Bigalke (2006) Interaction with one ganglioside and one protein receptor mediates the neurotoxicity of botulinum neurotoxins.Neurotox. Res. 9, 240.Google Scholar
  136. Sakamoto T, R Kaji, S Kozaki, K Oguma and T Harakawa (2006) Clinical application of stabilized low molecular weight (150kda) botulinum type A neurotoxin preparation for treating muscle hyperactivities.Neurotox. Res. 9, 224.Google Scholar
  137. Schroeder AS, S Berweck, SH Lee and F Heinen (2006) Botulinum toxin treatment of children with cerebral palsy — a short review of different injection techniques.Neutrotox. Res. 9(2,3), 189–196.Google Scholar
  138. Schuele SU and HO Lueders (2005) Botulinum toxin injections in the treatment of musician’s dystonia.Neurology 64(2), 341–343.PubMedGoogle Scholar
  139. Schurch B, M Storhrer, G Kramer, DM Schmid, G Gaul and D Hauri (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new altemative to anticholineergic drugs? Preliminary results.J. Urol. 164, 692–697.PubMedCrossRefGoogle Scholar
  140. Schurch B, M de Seze, P Denys, E Chartier-Kastler, F Haab, K Everaert, P Plante, B Perrouin-Verbe, C Kumar, S Fraczek and MF Brin (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month, study.J. Urol. 174, 196–200.PubMedCrossRefGoogle Scholar
  141. Schurch B, P Denys, K Everaeit, P Plante and S Fraczek (2006) Reductions in neurogenic urinary incontinence with botulinum toxin A and demographie predictors of response.Neurotox. Res. 9, 227.Google Scholar
  142. Selber P, R Wolf and K Graham (2006) Survivorship analysis of BoNT/A therapy for spastic equinus.Neurotox. Res. 9, 230.Google Scholar
  143. Shine N, T Christian, L Eaton and K Crawford (2006) Rapid sensitive and specific assay to measure the endoprotease activity of botulinum toxin type A.Neurotox. Res. 9, 240.Google Scholar
  144. Shipley S, A Pickett, N Panjwani, R France, L Riccalton-Banks, J McLaren, H Cox, R Quirk and K Shakesheff (2006) A new method for determining the potency of botulinum type A toxin complex (Dysport®): the neuromuscular junction assay.Neurotox. Res. 9, 235.Google Scholar
  145. Shone C, J Ferretra, A Boyer, N Cirino, C Egan, E Evans, J Kools and S Sharma (2006a) The 5th international conference on basic and therapeutic aspects of botulinum and tetanus neurotoxins. Workshop review: assays and detection.Neurotox. Res. 9(2,3), 205–216.PubMedGoogle Scholar
  146. Shone C, J Chaddock, P Marks, H Tranter, V Johnson and M Langford (2006b) Recombinant vaccines for the botulinum neurotoxins based on their LHN fragments.Neurotox. Res. 9, 242.Google Scholar
  147. Sikorra S, T Henke, S Swaminathan, T Galli and T Binz (2006) Identification of the amino acid residues rendering TI-VAMP resistant towards botulinum neurotoxin B.Neurotox. Res. 9, 242.Google Scholar
  148. Simpson LL, J-B Park and AB Maksymowych (2006) Identification of the epithelial cell population responsible for absorption of botulinum toxin.Neurotox. Res. 9, 240.Google Scholar
  149. Singh BR (2006) Botulinum neurotoxin structure engineering, and novel cellular trafficking and targeting.Neurotox. Res. 9(2,3), 73–92.PubMedGoogle Scholar
  150. Slater CR, KK Pang and JM Quinby (2006a) Long-term effects of botulinum toxin-A in muscles of children with cerebral palsy.Neurotox. Res. 9, 232.Google Scholar
  151. Slater CR, AA Rogozhin and KK Pang (2006b) Do newly formed synaptic contacts account for functional recovery from botulinum toxin type A?Neurotox. Res. 9, 221.Google Scholar
  152. Slawek J, L Findley, F Ahmed, J Larsen, Z Pirtosek and E Ruzicka (2006) Retrospective evaluation of the dose of Dysport® and Botox® in the management of dystonia-a comparison of dose ratio based on drug start.Neurotox. Res. 9, 236.Google Scholar
  153. Snuts J (2006) Botulinum toxin type A (Botox®)-a report of a 10 year safety follow-up.Neurotox. Res. 9, 245.Google Scholar
  154. Stacey B (2005) Management of peripheral neuropathic pain.Am. J. Phys. Med. Rehabil. 84, S4-S16.PubMedGoogle Scholar
  155. Steward LE, E Fernández-Salas, PE Garay, S Malik, RO Lewis and R Aoki (2006) A sensitive cell-based fluorescence resonance energy transfer (FRET) assay for botulinum neurotoxins.Neurotox. Res. 9, 239.Google Scholar
  156. Strayer MS, AB Maksymowych, KM Ruley, J-P Louboutin, LL Simpson and DS Strayer (2006) A denovirus immunization against botulinum toxin.Neurotox. Res. 9, 243.Google Scholar
  157. Sunter W, M Leong and M Royal (2006) The cervical dystonia subset of the mind registry database.Neurotox. Res. 9, 228.Google Scholar
  158. Trujillo C, R Ratts, A Tamayo, R Harrison and JR Murphy (2006) Trojan horse or proton force: finding the right partner(s) for toxin translocation.Neurotox. Res. 9(2,3), 63–71.PubMedGoogle Scholar
  159. Turkel C, B Bowen, J Liu and M Brin (2006) A pooled analysis of the safety of BoNT/A (Botox®) in the treatment of poststroke spasticity.Neurotox. Res. 9, 230.Google Scholar
  160. Verderio C, G Bonanno, C Montecucco and M Matteoli (2006) Penetration and translocation of fluorescent botulinum toxins in cultured hippocampal neurons.Neurotox. Res. 9, 219.Google Scholar
  161. Verplancke D, S Snape, CF Salisbury, PW Jones and AB Ward (2006) A randomised controlled trial of the management of early lower limb spasticity following acute acquired severe brain injury.Neurotox. Res. 9, 231.Google Scholar
  162. Vittal H and PJ Pasricha (2006) Botulinum toxin for gastrointestinal disorders: therapy and mechanisms.Neurotox. Res. 9(2,3), 149–159.PubMedCrossRefGoogle Scholar
  163. Williams D, LE Steward, MA Gilmore, Y Okawa, JA Webber and KR Aoki (2006) GFP-SNAP25 fluorescence release assay of WoNT proteolytic activity.Neurotox. Res. 9, 239.Google Scholar
  164. Wohlfarth K, C Müller, I Sassin, S Grafe and G Comes (2006) No spread of a new botulinum neurotoxin type A preparation in adjacent muscles.Neurotox. Res. 9, 236.Google Scholar
  165. Yablon S, S Daggett, F Lai and M Brin (2006) The development of toxin neutralizing antibodies with botulinum toxin type A (BoNT/A) treatment.Neurotox. Res. 9, 238.Google Scholar
  166. Yowler B, N Panjwani, A Pickett and C-L Schengrund (2006) Botulinum type A toxin-haemagglutinin complex binds to polysialylated gangliosides in physiological conditions.Neurotox. Res. 9, 240.Google Scholar
  167. Zhou Y, P Lindo and BR Singh (2006) Binding and internalization of hemagglutinin-33 of type A botulinum neurotoxin complex into human neuroblastoma cell SH-SY5Y.Neurotox. Res. 9, 241.Google Scholar
  168. Zvara P, MA Vizzard and MK Plante (2006) Botulinum toxin-A (BoNT/A) reduces bladder overactivity in rats with cyclophosphamide (CYP) induced cystitis and bladder outflow obstruction (BOO).Neurotox. Res. 9, 226.Google Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  1. 1.Department of Pharmacology, Quillen College of MedicineEast Tennessee State UniversityJohnson CityUSA
  2. 2.Molecular and Clinical PharmacologyUniversity of Chile, ICBM, Faculty of MedicineSantiago-7Chile

Personalised recommendations